Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8515249 | 0.91 | LPAR1 (0.41) | HIF1APPARGMCL1PTGS2KMT2A | |
| SCHEMBL935985 | 0.91 | HIF1A (0.39) | HIF1APPARGMCL1EGLN1KMT2A | |
| SCHEMBL8515015 | 0.88 | PTGS2 (0.40) | HIF1APPARGMCL1PTGS2PTGS1 | |
| SCHEMBL8513874 | 0.86 | HIF1A (0.39) | HIF1APPARGMCL1PTGS2KMT2A | |
| SCHEMBL8513539 | 0.86 | HIF1A (0.39) | HIF1APPARGMCL1PTGS2KMT2A | |
| SCHEMBL8514582 | 0.83 | MCL1 (0.41) | PPARGMCL1PTGS2KMT2ABCL2 | |
| SCHEMBL8515253 | 0.83 | KMT2A (0.51) | MCL1KMT2ABCL2BCL2L2 | |
| SCHEMBL8514743 | 0.83 | MCL1 (0.43) | HIF1APPARGMCL1PTGS2PTGS1 | |
| SCHEMBL8515326 | 0.83 | MCL1 (0.45) | HIF1AMCL1PTGS2TDP1 | |
| SCHEMBL8513005 | 0.83 | BCL2L1 (0.42) | MCL1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456767-B1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | claimed |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | claimed |
| EP-2456767-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-05-30 | — | — | EP | claimed |
| EP-2456767-B1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2456767-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HAYNES NANCY-ELLEN | 2011-01-27 | — | — | US | disclosed |
| WO-2011009845-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | HIF1A 3028/4885PPARG 152/4885MCL1 4634/4885 |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | HIF1A 3028/4885PPARG 152/4885MCL1 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.